Informizely customer feedback surveys

[Skip to content]

Southern Health
Search our Site

Sustain 7

Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes

Novo

The aim of this study is to evaluate the possible risks and the effectiveness of two medications for Type 2 diabetes, semaglutide and dulaglutide. Both of these drugs are used to reduce blood sugar levels, they can also be used to help with weight loss.

 

What does it involve?

 Eligible participants will recieve comprehensive medical care, including regular health checks as part of the screening process to ensure it is safe for you to take part.

The study will last approximately 47 weeks. This will include 40 weeks of treatment. You will be given either semaglutide or dulaglutide.

During these weeks you will have 8 visits to the study clinic and 2 phone contacts by the study team. At the visits a variety of tests will be conducted to check your physical health.


Inclusion Criteria
  • 18 years or older
  • Diagnosis of Type 2 diabetes
  • On a stable diabetes treatment (metformin)
  • Able to attend clinic appointments and phone contacts throughout the trial

 

To refer potential participants, or to request more information, please contact the research team:

Email: Chantelle.moorbey@southernhealth.nhs.uk

Phone: 02380 475 258

I would like to:

Return to Diabetes Studies

Return to Current Studies

Telephone the Research Team on 02380475258

Email the Research Team